A three-component lifestyle intervention (LSI) programme* was effective in improving the metabolic health and weight of reproductive-aged women with polycystic ovarian syndrome (PCOS), according to data presented at ESHRE 2021.
A delay of up to 180 days in initiating in vitro fertilization (IVF) does not appear to affect live birth rates among women with infertility and diminished ovarian reserve, according to a retrospective cohort study presented at ESHRE 2021.
COVID-19 infection does not appear to adversely affect ovarian reserve, and thus, the chance of success from assisted reproductive treatment likely remains the same as before infection, suggests a small study presented at ESHRE 2021.
Linzagolix treatment continues to reduce menstrual blood loss (MBL) and pain severity, while improving haemoglobin (Hb) level and quality of life (QoL) up to 52 weeks in women with uterine fibroids, according to two phase III randomized clinical trials presented at ESHRE 2021.
Women who undergo artificial cycle frozen-thawed embryo transfer (AC-FET) may have an elevated risk of preeclampsia and pregnancy-induced hypertension (PIH) compared with women who undergo ovulatory cycle frozen-thawed embryo transfer (OC-FET) or in vitro fertilization-fresh transfer (fresh-ET), according to a nationwide cohort study from France presented at ESHRE 2021.
The risk of cancer is not elevated in children and young adults who were conceived after assisted reproductive technology (ART), including in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), and fresh or frozen embryo transfer, compared with those conceived naturally, according to a study presented at ESHRE 2021.
The combination of relugolix 40 mg plus oestradiol 1 mg and norethindrone acetate 0.5 mg (relugolix-CT) continued to reduce dysmenorrhoea and non-menstrual pelvic pain (NMPP) through 52 weeks in premenopausal women with endometriosis, according to the SPIRIT extension* study presented at ESHRE 2021.
Even moderate alcohol intake, particularly during the second half of the menstrual cycle, should be avoided by women who want to get pregnant, according to a new study that was touted as the first to look at fecundability during the menstrual cycle phases.